Kisspeptin for PCOS: Frequently asked questions

Verify that your PCOS model actually exhibits elevated basal kisspeptin levels before attempting kisspeptin intervention. Not all PCOS models replicate the hyperkinetic GnRH pulse generator seen in human PCOS. Letrozole-induced models, for instance, cause anovulation through direct aromatase inhibition without necessarily dysregulating kisspeptin. DHT or testosterone-induced models more reliably produce kisspeptin-driven LH hypersecretion. If your model is appropriate and dosing is correct, check peptide storage conditions. Even brief temperature excursions above 8°C can denature kisspeptin-10 irreversibly.

Discard it immediately and prepare a fresh batch at lower concentration. Cloudiness indicates peptide aggregation. Aggregated kisspeptin has unpredictable bioavailability and may produce inconsistent results across experimental replicates. Most aggregation occurs when peptide concentration exceeds 1 mg/mL or when reconstitution occurs at temperatures above 25°C. Use chilled sterile water, vortex gently rather than shaking vigorously, and target 0.5 mg/mL final concentration to maximize stability.

Focus on the hyperresponder PCOS phenotype, where suppressing excessive kisspeptin signaling is the therapeutic goal. Peptide 234, a selective KISS1R antagonist developed by Imperial College researchers, blocks kisspeptin-induced GnRH release in rodent studies without affecting basal GnRH tone. Dosing protocols use continuous subcutaneous infusion at 10 nmol/kg/day to maintain steady receptor blockade. No human safety data exists yet. This remains a preclinical research direction requiring IND approval before translational work.

Current protocols use subcutaneous infusion pumps that deliver kisspeptin-54 over 6–8 hours, twice weekly. This requires a programmable pump similar to an insulin pump, loaded with reconstituted kisspeptin stored at 2–8°C. The infusion runs while you sleep or go about daily activities. If nasal spray formulations reach Phase 3 trials and are approved, dosing would shift to 2–3 nasal administrations per day, similar to desmopressin or oxytocin nasal sprays. Oral delivery is not viable because gastric acid degrades peptides within minutes.

No published trial has tested combination therapy, but the mechanisms are redundant. Clomiphene works by blocking estrogen negative feedback to disinhibit GnRH secretion; kisspeptin works by directly stimulating GnRH neurons. Adding kisspeptin while on clomiphene would likely cause GnRH overstimulation, excessive LH secretion, and risk of ovarian hyperstimulation syndrome. The more relevant question is whether kisspeptin could replace clomiphene in women who are clomiphene-resistant. And early data suggest yes, because kisspeptin doesn't depend on intact estrogen receptor signaling.

Probably not as monotherapy. Phase 2 trial data show that kisspeptin for PCOS research is effective primarily in lean PCOS phenotypes (BMI under 28 kg/m², fasting insulin under 15 µIU/mL). Hyperinsulinemia interferes with kisspeptin signaling at the hypothalamic level, likely through insulin's direct effects on arcuate neurons or elevated leptin, which blunts kisspeptin neuron responsiveness. If you have metabolic PCOS, you would likely need metformin or a GLP-1 receptor agonist alongside kisspeptin to restore insulin sensitivity before the neuroendocrine intervention works.